Shattuck Labs, Inc.

NasdaqGS STTK

Shattuck Labs, Inc. Current Liabilities for the quarter ending September 30, 2024

Shattuck Labs, Inc. Current Liabilities is NA for the quarter ending September 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Shattuck Labs, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 14.06 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqGS: STTK

Shattuck Labs, Inc.

CEO	Dr. Taylor H. Schreiber M.D., Ph.D.
IPO Date	Oct. 9, 2020
Location	United States
Headquarters	500 West 5th Street
Employees	75
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Key trends

Past 5 years